阿扎胞苷用于治疗患有骨髓增生异常综合症的患者。
Azacitidine is used to treat patients with myelodysplastic syndromes.
他的团队探讨骨髓增生异常综合征的患者血红蛋白合成异常的情况。
His team investigated the state of abnormal composition of hemoprotein in myelodysplastic syndrome.
结论癌细胞的类型恶性程度与骨髓增生度有关。
Conclusion The type and malignant degree of cancer cell were related to hyperplastic degree of marrow.
活动性高及骨髓增生度好的患者对治疗的反应好。
The patients with active disease and those with active bone marrow hyperplasia have good response to the treatment.
骨髓增生异常综合征是一种造血干细胞克隆异常性疾病。
Myelodysplastic syndrome (MDS) is a clonal disorder of the hematopoietic stem cell.
目的探讨骨髓增生性疾病致门静脉高压症的诊断及治疗。
Objective to discuss the diagnosis and treatment of portal hypertension secondary to myeloproliferative diseases.
目的探讨小儿骨髓增生异常综合征（MDS）的临床特点。
AbstractObjectiveTo study the clinical characteristics and prognosis factors of myelodysplastic syndrome (MDS) in children.
结论：骨髓活检是确诊低增生型骨髓增生异常综合征的必要手段。
Conclusion: the diagnose of hypoplastic MDS depends on the trephine biopsy.
目的探讨骨髓增生异常综合征（MDS）合并自身免疫性疾病的特点。
Objective To explore the character of the myelodysplastic syndrome(MDS) with autoimmune disorders (AID).
目的探讨免疫细胞化学法在骨髓增生异常综合征（MDS）诊断价值。
Objective To explore the value of immunocytochemistry in diagnosis of myelodysplastic syndromes( MDS).
我们研究了硼替佐米单药在骨髓增生异常综合征中应用的有效性和安全性。
We performed a study on efficacy and safety of bortezomib as a single agent in patients with myelodysplastic syndromes (MDS).
骨髓增生异常，往往伴有低血小板计数，其中某些病人有向白血病转化的倾向。
Myelodysplasia, which is associated with low platelet counts, predisposes some patients to leukemia.
目的：评估骨髓活检在骨髓增生异常综合征尤其是低增生型病例时的诊断价值。
Objective:To explore the value of bone marrow biopsy in diagnosing Myelodysplastic Syndrome(MDS) especially in the cases of MDS with hypoplasia.
这样的脾肿大通常预示有骨髓增生型疾病，例如慢性髓性白血病或骨髓纤维化。
Such massive splenomegaly is usually indicative of some myeloproliferative disease such as chronic myelogenous leukemia or myelofibrosis.
多大剂量？多少频率？多长时间？骨髓增生异常综合征新疗法的临床应用指南。
How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes.
肾阴虚型骨髓增生程度重度减低，无巨核细胞，骨髓活检以造血细胞缺乏为特点。
The deficiency of Yin type of kidney, hyperplasia of marrow diminished seriously, without megakaryocyte, be characterized by lack of hematoblast in live examination.
结论髓系肉瘤可孤立出现或发生于各种骨髓增生性疾病的病程中或经治疗缓解后。
Conclusions Myeloid sarcoma may precede, develop in a background of myeloproliferative disorder or even after remission of the disease.
苯中毒患者的骨髓涂片中粒红比值、巨核细胞数量随着骨髓增生程度降低而降低。
Bone marrow hypoplasia coincided with the reduction of the ratios of granulocytes to erythrocytes as well as the megakaryocytes count. Conclusion Bone marrow biopsy and smear examination are valu…
结合各例骨髓增生活跃程度，表明BCR/ABL基因表达水平可以反映治疗效果。
These implied that the expression of BCR/ABL gene was related to the active proliferation of bone marrow cells.
实验证明：T - 2毒素可抑制肿瘤细胞生长，对骨癌及骨髓增生异常有良好的杀伤。
The experiment shows that the T-2 toxin is capable of inhibiting the growth of tumor cells and has good killing effect on the bone cancers and myeloproliferative disorder.
方法10例19 ~58岁骨髓增生异常综合征的患者，选择部分脾动脉栓塞术治疗。
Methods 10 patients, ages: 19 ~ 58 years old, troubling with MDS, accepted splenic artery part embolization.
本研究探讨血小板糖蛋白特异性抗体在骨髓增生异常综合征（MDS）患者发病中的作用。
The aim of this study was to find platelet specific autoantibodies against glycoproteins in myelodysplastic syndrome(MDS)and to explore its role in pathogenesis of MDS.
丙卡巴肼、氮芥和异环磷酰胺：可增加患骨髓增生异常综合症和急性粒细胞白血病的风险。
Procarbazine, nitrogen mustard, and ifosfamide, which can increase risk for myelodysplastic syndromes and acute myelogenous leukemia.
在慢性ITP患者中，免疫系统在破坏血小板，而病人的骨髓增生往往是无法弥补这一损失。
In patients with chronic ITP, the immune system is believed to destroy platelets and the patient's bone marrow is often unable to compensate for this loss.
骨髓增生异常综合征（MDS）患者的外周血白细胞减少、免疫功能低下和感染都是临床不可避免的问题。
The infection'manifestation with the decreased white blood cell and immune function is an unavoidable problem in the patients with myelodysplastic syndrome (MDS).
提示在所检病例中存在HHV?6感染，其中与急性白血病、淋巴瘤及骨髓增生异常综合症关系尤为密切。
The results show that the examined patients are infected by HHV 6, which has a good relationship with leukemia, lymphoma, myeloproliferative disorder syndrome, and multiple myeloma.
氮杂胞苷（Azacitidine），用于治疗骨髓增生异常综合征（MDS）一种罕见的恶性血液肿瘤。
Azacitidine is used to treat patients with myelodysplastic syndromes (usually abbreviated, a bit oddly, to MDS), a group of rare and deadly blood malignancies.
目的：调查白血病和骨髓增生异常综合征(MDS)患者红细胞酶和同工酶谱改变的患病率，并研究其临床意义。
Objective: To define the prevalence of acquired red cell enzymopathy in leukemia and MDS patients and explore its clinical significance.
目的：调查白血病和骨髓增生异常综合征(MDS)患者红细胞酶和同工酶谱改变的患病率，并研究其临床意义。
Objective: To define the prevalence of acquired red cell enzymopathy in leukemia and MDS patients and explore its clinical significance.
应用推荐